Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273026 | 1.00 | LMNA (0.64) | LMNATSHRNPC1MAPTMEN1 | |
| SCHEMBL1835550 | 1.00 | LMNA (0.64) | LMNATSHRNPC1MAPTMEN1 | |
| SCHEMBL4045199 | 0.94 | LMNA (0.58) | LMNATSHRNPC1MAPTMEN1 | |
| SCHEMBL5949941 | 0.89 | LMNA (0.78) | LMNATSHRMAPTPOLBNPSR1 | |
| SCHEMBL12306453 | 0.83 | MAPT (0.47) | LMNATSHRNPC1MAPTMEN1 | |
| SCHEMBL19026295 | 0.83 | TSHR (0.47) | LMNATSHRNPC1MEN1KMT2A | |
| SCHEMBL4040218 | 0.82 | LMNA (0.53) | LMNATSHRNPC1MAPTPOLB | |
| SCHEMBL10700083 | 0.82 | TSHR (0.55) | LMNATSHRNPC1MAPTMEN1 | |
| SCHEMBL5961837 | 0.81 | NPC1 (0.46) | LMNATSHRNPC1 | |
| SCHEMBL1496625 | 0.81 | LMNA (0.67) | LMNATSHRMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321287-B1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-8729113-B2 | 4,5-dihydro-oxazol-2yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8357712-B2 | — | — | 2013-01-22 | — | — | US | disclosed |
| US-8242153-B2 | 4,5-dihydro-oxazol-2YL derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120165294-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | GALLEY GUIDO (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20110144333-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | GALLEY GUIDO | 2011-06-16 | — | — | US | disclosed |
| EP-2321287-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-7671089-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010010014-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009140984-A1 | ANHYDROUS AND HYDRATE FORMS OF CRYSTALLINE 2- ( (2S, 3R, 4E, 6E, 1OE, 12S) -13- (4-FLUOROPHENOXY) -2,3, 12- (TRIHYDROXYTRIDECA-4, 6, 10-TRIEN-8-YNYL) OXY) ACETIC ACID | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
| US-20080103200-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7323585-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060020028-A1 | Levodopa prodrugs, and compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144333-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885TSHR 230/4885NPC1 601/4885 |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885TSHR 230/4885NPC1 601/4885 |
| US-20060020028-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | LMNA 2387/4885TSHR 2158/4885NPC1 3417/4885 |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885TSHR 230/4885NPC1 601/4885 |
| US-20120165294-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | LMNA 3212/4885TSHR 230/4885NPC1 601/4885 |
| US-20080103200-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | LMNA 2387/4885TSHR 2158/4885NPC1 3417/4885 |
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | LMNA 2387/4885TSHR 2158/4885NPC1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.